International Skeptics Forum - View Single Post - The all-new "US Politics and coronavirus" thread pt. 3

Skeptic Ginger · 11th December 2020, 05:30 PM

According to the Regeneron webpage: Re 3rd phase clinical trials

Quote:

CASIRIVIMAB AND IMDEVIMAB
SARS-CoV-2 Virus Multi-Antibody Therapy Treatment for certain hospitalized and non-hospitalized patients with COVID-19; prevention of COVID-19 in household contacts of diagnosed patients

Company news releases REGENERON’S CASIRIVIMAB AND IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 IS FIRST COMBINATION THERAPY TO RECEIVE FDA EMERGENCY USE AUTHORIZATION

Quote:

Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients

Initial doses will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation program ...

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

11th December 2020, 05:30 PM	#8
Skeptic Ginger Nasty Woman Join Date: Feb 2005 Posts: 87,756	According to the Regeneron webpage: Re 3rd phase clinical trials Quote: CASIRIVIMAB AND IMDEVIMAB SARS-CoV-2 Virus Multi-Antibody Therapy Treatment for certain hospitalized and non-hospitalized patients with COVID-19; prevention of COVID-19 in household contacts of diagnosed patients Company news releases REGENERON’S CASIRIVIMAB AND IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 IS FIRST COMBINATION THERAPY TO RECEIVE FDA EMERGENCY USE AUTHORIZATION Quote: Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients Initial doses will be made available to approximately 300,000 patients, with no medication out-of-pocket costs, under U.S. government allocation program ... The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.